Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 1525 participants.

Also called NCT03621501

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,525 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03621501
Other papers using this trial's data
  • Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial Lancet (London, England), 2023-04-08 DOI, PubMed 36889333
  • Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome: 2-Year Results of the BIOVASC Study JACC. Cardiovascular interventions, 2024-12-23 DOI, PubMed 39722269

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03621501. Randomized; single masking; primary purpose treatment. Start 2018-06-22 (actual); primary completion 2022-10-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease
Acronym
BioVasc
Condition
Acute Coronary Syndrome
Lead sponsor
Erasmus Medical Center (class: other)
Collaborator
Biotronik SE & Co. KG (class: industry)

Record details

Record id
cardio:ct-nct03621501
Content hash
021777108ce451446f19f11f95c37870449baaefd042bbef9e2e7cea33ffb3fb